保险公司对中重度溃疡性结肠炎和克罗恩病管理指南的依从性差
该研究检索了美国前50家保险公司对5种生物制剂/小分子药物的公开保单,并与美国胃肠病学会/美国胃肠病学协会指南比较。
要点
- 多数保险公司要求先失败于类固醇和免疫调节剂才批准生物制剂。
- 对ACG/AGA指南的依从率范围为5.8%至58.8%。
- 仅少数保单允许克罗恩病或溃疡性结肠炎一线生物制剂治疗。
核心结论
- 几乎所有保险公司都要求先失败于类固醇和免疫调节剂才可使用生物制剂,需改进以改善患者获得标准治疗的机会。
研究设计与样本
- 检索美国前50家保险公司对5种生物制剂/小分子药物的公开保单,并与美国胃肠病学会/美国胃肠病学协会指南比较。
主要发现
- 对ACG/AGA指南的依从率范围为5.8%至58.8%。
- 仅14.71%的克罗恩病保单和17.65%的溃疡性结肠炎保单允许一线使用任何生物制剂。
关键数值与推荐
- 对ACG/AGA指南的依从率范围为5.8%至58.8%。
- 允许一线使用任何生物制剂的保单比例:克罗恩病14.71%,溃疡性结肠炎17.65%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Moderate-to-severe inflammatory bowel disease treatment transitioned from step-up therapy to induction of remission with a biologic agent, but insurance coverage varies. METHODS: Top 50 insurance companies were searched for publicly available policies for 5 biologic/small molecule agents. Data regarding coverage requirements were compared with American College of Gastroenterology/American Gastroenterological Association guidelines. RESULTS: Thirty-four insurers had public policies. Adherence to American College of Gastroenterology/American Gastroenterological Association guidelines ranged from 5.8% to 58.8%. Only 14.71% and 17.65% of policies permitted any first-line biologic therapy in Crohn's disease and in ulcerative colitis. DISCUSSION: Nearly every insurance company required failure of steroids and immunomodulators before biologic therapy. Further work is required to improve patient access to standard-of-care treatment.
引用
- Anderson KL, Anand R, Feuerstein JD, et al. Insurance Companies' Poor Adherence to Guidelines for Moderate-to-Severe Ulcerative Colitis/Crohn's Disease Management. Am J Gastroenterol. 2024. PMID: 38417043. doi:10.14309/ajg.0000000000002720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。